GlassScriptPhysician profile
Melea Lenore Mullican
NPI 1114557030
$929.78
in general payments reported to CMS, 2019-2025
23 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.56 · 2022: $238 · 2023: $139 · 2024: $215 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $123.38 | 2022-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $120.71 | 2023-2025 | |
| Abbvie INC. | $102.07 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $81.56 | 2022-2025 | Qinlock, Romvimza |
| Array Biopharma INC | $53.75 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Seagen INC. | $51.99 | 2021-2023 | Tukysa |
| Pfizer INC. | $46.29 | 2024-2025 | |
| Daiichi Sankyo INC. | $38.65 | 2021-2024 | Enhertu |
| Lilly USA, LLC | $36.29 | 2021-2022 | |
| Eisai INC. | $35.99 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2024 | Gilotrif |
| Pharmacosmos Therapeutics INC. | $24.38 | 2022 | |
| Pharmaessentia USA Corporation | $22.44 | 2023 | Besremi |
| Sobi, INC | $20.25 | 2022 | |
| Puma Biotechnology, INC. | $20.04 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.25 | 2022 | |
| Incyte Corporation | $18.01 | 2022 | |
| Morphosys, US INC. | $17.45 | 2022 | |
| Aveo Pharmaceuticals, INC. | $16.79 | 2025 | |
| Glaxosmithkline, LLC. | $14.32 | 2023 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2024 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $13.08 | 2021 | |
| Merck Sharp & Dohme LLC | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melea Mullican listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.